Drug Development

Articles

Also, Shire recalls "Daytrana" patch, Chromatide forms Scientific Advisory Board, more...

Company and People Notes: Gilead Sciences to Expand Headquarters and add 1900 Jobs, WuXi Appoints Rujian Ma as VP of Synthetic Chemistry, More

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

The specialty drug company King Pharmaceuticals is seeking to acquire the specialty pharmaceutical company Alpharma (Bridgewater, NJ) through an unsolicited bid of $33 per share or $1.4 billion in cash. Alpharma has rejected the bid.

King Pharmaceuticals Bids $1.4 Billion for Alpharma

The Synthetic Organic Chemical Manufacturers Association (SOCMA) is expressing trade concerns with the European Union's REACH (Registration, Evaluation, Authorization, and Restriction of Chemicals) regulation, a new European Union policy on chemicals and their safe use.

SOCMA Expresses Trade Concerns with REACH Implementation

Also, Tekmira will collaborate with Bristol-Myers Squibb, Helicos Biosciences appoints Steve Lombardi CEO, more...

Company and People Notes: CSL to Acquire Talecris, Benda Appoints George Zhou COO, More...

Actavis Totowa LLC, the US subsidiary of the generic drug manufacturer Actavis Group, is announcing a voluntary recall to the retail level of all drug products manufactured at its Little Falls, New Jersey, facility. This is a precautionary, voluntary action by Actavis following an inspection conducted by the Food and Drug Administration earlier this year.

Actavis Voluntary Recalls Products for GMP Violations

Also, Ortho Biotech recalls one lot of "Procrit" due to cracked vials, more appointments at Actavis, more...

Company and People Notes: Genentech Rejects Roche's Bid, TorreyPines CEO Retires, More...

The House Committee on Energy and Commerce issued a revised discussion draft to the Food and Drug Administration Globalization Act of 2008.

Revised Discussion Draft of FDA Globalization Act Further Tightens the Supply Chain

Bristol-Myers Squibb is seeking to acquire the biopharmaceutical company ImClone Systems (New York) for $4.5 billion or $60 per share. BMS currently holds a 17% stake in ImClone.

BMS Bids $4.5 Billion for ImClone Systems

Also, Bilcare Global Clinical Supplies opens new headquarters in San Francisco, Sigurdur Oli Olafsson named CEO of Actavis Group, more...

Company and People Notes: Meda will Acquire Valeant's Western and Eastern European Businesses, Catalent Names George L. Fotiades Interim President and CEO, More...

The pharmaceutical industry?s outsourcing practices receive increased attention as Congress evaluates the role of outsourcing in drug-safety issues.

Ingredients